MX364929B - Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. - Google Patents

Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.

Info

Publication number
MX364929B
MX364929B MX2015012350A MX2015012350A MX364929B MX 364929 B MX364929 B MX 364929B MX 2015012350 A MX2015012350 A MX 2015012350A MX 2015012350 A MX2015012350 A MX 2015012350A MX 364929 B MX364929 B MX 364929B
Authority
MX
Mexico
Prior art keywords
agonists
receptor
carboxamide
quinoline
derivatives
Prior art date
Application number
MX2015012350A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012350A (es
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Anil Karbhari Shinde
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2015012350A publication Critical patent/MX2015012350A/es
Publication of MX364929B publication Critical patent/MX364929B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • G01N33/57505
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
MX2015012350A 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. MX364929B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1199CH2013 IN2013CH01199A (enExample) 2013-03-20 2013-10-18
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
MX2015012350A MX2015012350A (es) 2016-05-09
MX364929B true MX364929B (es) 2019-05-14

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012350A MX364929B (es) 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.

Country Status (18)

Country Link
US (1) US9790211B2 (enExample)
EP (1) EP2976337B1 (enExample)
JP (1) JP6185650B2 (enExample)
KR (1) KR101815307B1 (enExample)
CN (1) CN105164119B (enExample)
AP (1) AP2015008742A0 (enExample)
AU (1) AU2013382944B2 (enExample)
BR (1) BR112015024060A2 (enExample)
CA (1) CA2907620C (enExample)
DK (1) DK2976337T3 (enExample)
EA (1) EA029365B1 (enExample)
ES (1) ES2674993T3 (enExample)
IN (1) IN2013CH01199A (enExample)
MX (1) MX364929B (enExample)
NZ (1) NZ712369A (enExample)
SG (1) SG11201507763RA (enExample)
WO (1) WO2014147636A1 (enExample)
ZA (1) ZA201506804B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368214B (es) * 2015-02-13 2019-09-24 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664805A1 (en) 1992-10-13 1995-08-02 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht 4? receptor antagonists
KR950704328A (ko) 1992-11-05 1995-11-17 데이비드 로버츠 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists)
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
AU2001225664A1 (en) * 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
PT1638959E (pt) * 2003-06-19 2007-12-12 Janssen Pharmaceutica Nv 4-(aminometil)piperidinobenzamidas antagonistas de 5ht4
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
US7834010B2 (en) 2003-12-23 2010-11-16 Serodus As Modulators of peripheral 5-HT receptors
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
WO2006090224A1 (en) 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives
DE602006010563D1 (de) 2005-07-22 2009-12-31 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
JP6023926B2 (ja) * 2010-02-12 2016-11-09 株式会社AskAt 認知症治療のための5−ht4受容体アゴニスト
IN2012DN06631A (enExample) 2010-02-16 2015-10-23 Pfizer

Also Published As

Publication number Publication date
MX2015012350A (es) 2016-05-09
AP2015008742A0 (en) 2015-09-30
HK1217483A1 (zh) 2017-01-13
ZA201506804B (en) 2016-07-27
SG11201507763RA (en) 2015-10-29
US9790211B2 (en) 2017-10-17
JP6185650B2 (ja) 2017-08-23
CA2907620A1 (en) 2014-09-25
CN105164119B (zh) 2017-12-08
EA201591844A1 (ru) 2016-08-31
CN105164119A (zh) 2015-12-16
WO2014147636A8 (en) 2014-12-04
DK2976337T3 (en) 2018-07-16
IN2013CH01199A (enExample) 2015-08-14
AU2013382944B2 (en) 2016-08-04
EA029365B1 (ru) 2018-03-30
JP2016516089A (ja) 2016-06-02
KR20160004274A (ko) 2016-01-12
AU2013382944A1 (en) 2015-10-08
EP2976337A1 (en) 2016-01-27
EP2976337B1 (en) 2018-05-02
CA2907620C (en) 2018-03-13
ES2674993T3 (es) 2018-07-05
BR112015024060A2 (pt) 2017-07-18
NZ712369A (en) 2016-11-25
US20160280694A1 (en) 2016-09-29
KR101815307B1 (ko) 2018-01-04
WO2014147636A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
MX2024011839A (es) Compuetos heterociclicos utiles en el tratamiento de enfermedades.
ECSP16083602A (es) Derivados de quinolina como inhibidores smo
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
MX2017014375A (es) Moduladores del ccr2.
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
UY36311A (es) Indazoles sustituidos con bencilo
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
UY34472A (es) Derivados modificados de 4-fenil-piridina
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina

Legal Events

Date Code Title Description
FG Grant or registration